Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis
Open Access
- 9 January 2026
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (3) , 107713
Abstract
No abstract availableKeywords
Funding Information
- Drugs for Neglected Diseases initiative (MVP322/19)
- Instituto de Salud Carlos III (PI22/00009)
- ZonMw (91617140)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Vetenskapsrådet (CTRI/2017/04/008421)
- Vetenskapsrådet (NCT03399955)
- Vetenskapsrådet (VR 2022-01251)
- International Centre for Diarrhoeal Disease Research, Bangladesh
- Direktion für Entwicklung und Zusammenarbeit
- World Health Organization
- Médecins Sans Frontières
- Agence Française de Développement
- Ministerie van Buitenlandse Zaken
This publication has 27 references indexed in Scilit:
- Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia—authors’ responseJournal of Antimicrobial Chemotherapy, 2025
- Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern AfricaThe Journal of Infectious Diseases, 2024
- Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South AsiaJournal of Antimicrobial Chemotherapy, 2024
- Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis PatientsClinical Pharmacokinetics, 2021
- Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics studyThe Lancet Microbe, 2021
- Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand FliesClinical Infectious Diseases, 2018
- Analysis of drug combinations: current methodological landscapePharmacology Research & Perspectives, 2015
- Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 2006
- Sodium stibogluconate cardiotoxicity and safety of genericsTransactions of the Royal Society of Tropical Medicine and Hygiene, 2003
- Post-kala-azar dermal leishmaniasisThe Lancet Infectious Diseases, 2003